| Ticker Symbol: | EURX |
|---|---|
| Exchange: | NASD |
| Contact Info: | |
| CEO/President: | |
| Industry: | Medical - Drugs / Standard Industry Code: 2834 |
| Description: | EURAND is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products using their proprietary drug formulation technologies.They are dedicated to the continued development and commercialization of breakthrough products that better satisfy patients\' needs. Their research efforts are focused on the development of treatment options with enhanced efficacy, superior safety and convenient dosing. |
| Shares Outstanding: | 45,000 (000) | Market Value: | 378,480 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 15.80% | Number of Inst.Shareholders: | N/A% |
| Last Quarter Sales: | 40.90 ($Mil.) | Last Quarter Net Income: | 35.98 ($Mil.) |
| Last Quarter EPS: | -0.06 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | 0.41 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| PFIZER INC | -30.30 | 15.83 | |
| JOHNSON AND JOH | -16.60 | 57.92 | |
| BRISTOL MYERS S | -24.70 | 19.55 | |
| SCHERING PLOUGH | -48.10 | 14.63 | |
| MERCK CO INC | -54.30 | 26.72 |
